Johnson Financial Group Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,740 shares of the company’s stock after acquiring an additional 369 shares during the quarter. Johnson & Johnson makes up 0.7% of Johnson Financial Group Inc.’s portfolio, making the stock its 22nd biggest position. Johnson Financial Group Inc.’s holdings in Johnson & Johnson were worth $5,736,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently made changes to their positions in the company. University of Texas Texas AM Investment Managment Co. bought a new position in Johnson & Johnson during the 4th quarter worth approximately $31,000. Sofos Investments Inc. raised its position in shares of Johnson & Johnson by 172.0% during the 1st quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock valued at $33,000 after acquiring an additional 726 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $35,000. Advocacy Wealth Management Services LLC lifted its stake in Johnson & Johnson by 38.2% during the first quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock worth $39,000 after purchasing an additional 83 shares during the last quarter. Finally, Lion Street Advisors LLC acquired a new position in Johnson & Johnson in the first quarter worth $45,000. 68.51% of the stock is owned by institutional investors.
JNJ has been the topic of a number of recent research reports. SVB Leerink reduced their price target on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Cantor Fitzgerald reiterated a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Citigroup lifted their target price on Johnson & Johnson from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, April 15th. Stifel Nicolaus upped their target price on Johnson & Johnson from $140.00 to $155.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $163.47.
Shares of NYSE:JNJ traded up $1.69 on Wednesday, hitting $147.65. The company’s stock had a trading volume of 1,064,067 shares, compared to its average volume of 9,785,549. The company has a market capitalization of $388.08 billion, a price-to-earnings ratio of 19.31, a price-to-earnings-growth ratio of 3.20 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.05 and a current ratio of 1.31. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The stock’s 50-day moving average is $148.86 and its two-hundred day moving average is $143.59.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.10 earnings per share. Equities analysts expect that Johnson & Johnson will post 7.68 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.74%. The ex-dividend date was Friday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s payout ratio is 46.54%.
In related news, Director William D. Perez acquired 500 shares of the company’s stock in a transaction on Friday, March 13th. The shares were purchased at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the purchase, the director now owns 16,030 shares in the company, valued at $2,046,870.70. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: How does quantitative easing work?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.